AstraZeneca Pharma India (AZPIL) announced that it has received Import & Market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India, subject to the receipt of further related statutory approvals and licenses.
Durvalumab provides a treatment option for patient with locally advanced, unresectable Non-Small Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma.
Durvalumab is a patented product of AstraZeneca global.
Gagan Singh, Managing Director, AstraZeneca Pharma India, said, ''The import and market permission for Durvalumab for unresectable stage III Non-Small Cell Lung Cancer (NSCLC) and locally advanced or metastatic urothelial carcinoma is a significant milestone for patients who have currently limited treatment options. In India, approximately one third of patients with NSCLC are present with Stage III disease and we are excited to bring the first immunotherapy into this setting for patients.''
Shares of the company gained Rs 42.5, or 3.14%, to trade at Rs 1,395.00. The total volume of shares traded was 26,022 at the BSE (10.52 a.m., Friday).